Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 648

Sort by

Sort Order Select

Journal Articles

T Cell Determinants of Response and Resistance to PD-1 Blockade in Richter's Transformation

Blood (2019) 134 (Supplement_1): 680.

https://doi.org/10.1182/blood-2019-125904

Published: 2019

Journal Articles

A Multicenter Study of Romiplostim to Treat Chemotherapy-Induced Thrombocytopenia in Solid Tumors and Lymphoid Malignancies

Hanny Al-Samkari, MD, Aric D Parnes, MD, Katayoon Goodarzi, MD, James I Weitzman, MD, Jean M. Connors, MD, David J. Kuter

Blood (2019) 134 (Supplement_1): 389.

https://doi.org/10.1182/blood-2019-123864

Published: 2019

Journal Articles

High-Throughput BCR Sequencing and Single-Cell Transcriptomics Reveal Distinct Transcriptional Profiles Associated with Subclonal Evolution of Follicular Lymphoma

Cornelis A.M. van Bergen, Marvyn T. Koning, BSc, Edwin Quinten, Agnieszka Mykowiecka, MSc, Julieta Sepulveda, MSc, Ramin Monajemi, PhD, Ruben A.L. De Groen, Joost Vermaat, MD PhD, Susan L. Kloet, PhD, Szymon M. Kielbasa, PhD, Marcelo A. Navarrete, PhD, Pawel Górecki, PhD, Hendrik Veelken, MD PhD

Blood (2019) 134 (Supplement_1): 298.

https://doi.org/10.1182/blood-2019-130508

Published: 2019

Journal Articles

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Connie Suen, PharmD, Stephen J Schuster, MD, Jakub Svoboda, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Kyle Robinson, MD, Elise A. Chong, MD, Joanna M Rhodes, MD, Emily C. Ayers, MD, Alison W. Loren, MD MSCE, Edward A. Stadtmauer, MD FACP, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5247.

https://doi.org/10.1182/blood-2019-128148

Published: 2019

Journal Articles

Clinical Significance of KIR Genotype in Patients with Methotrexate-Associated Lymphoproliferative Disorders

Norina Tanaka, MD PhD, Aya Watanabe, MD, Suguru Honda, MD, Mitsuko Kobayashi, Yan-Hua Wang, MD, Yuki Iizuka, MD, Michiko Ryuzaki, MD, Midori Ishiyama, MD PhD, Akihito Shinohara, MD PhD, Hiroshi Kazama, MD PhD, Shotaro Hagiwara, MD PhD, Kentaro Yoshinaga, MD PhD, Katsunori Ikari, MD PhD, Masayuki Shiseki, MD PhD, Masayoshi Harigai, MD PhD, Junji Tanaka, MD PhD

Blood (2019) 134 (Supplement_1): 5219.

https://doi.org/10.1182/blood-2019-127836

Published: 2019

Journal Articles

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Argiris Symeonidis, MD PhD, Sotirios Papageorgiou, MD PhD, Antonis Patrinos, MD, Maria Melachrinou, MD PhD, Alexandra Kourakli, MD PhD, Vassiliki Pappa, MD, Maria K. Angelopoulou, MD, Anastasia Sioni, Nikolaos Kanellias, MD, Sofia Chatzileontiadou, MD, Eleftheria Hatzimichael, Panagiotis Zikos, Anastasia Pouli, MD PhD, Maria Papaioannou, Evangelos Terpos, MD PhD, Gerasimos Pangalis, MD, Theodoros P. Vassilakopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 5340.

https://doi.org/10.1182/blood-2019-130219

Published: 2019

Journal Articles

Niveau, a Phase 3 Study for Pts with B- or T-Cell Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivo lumab in Combination with G e mcitabine, Ox a liplatin (GemOx), Plus Rit u ximab (R) in Case of B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 5311.

https://doi.org/10.1182/blood-2019-129362

Published: 2019

Journal Articles

Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study

Suvi-Katri Leivonen, PhD, Judit Jørgensen, MD PhD, Thomas Stauffer Larsen, MD PhD, Annika Pasanen, MD PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Helle M Toldbod, PhD, Francesco d'Amore, MD PhD, Sirpa Leppa, MD PhD

Blood (2019) 134 (Supplement_1): 5314.

https://doi.org/10.1182/blood-2019-129113

Published: 2019

Journal Articles

Patients with Bone and Bone Marrow Involvement Had Better OS and PFS in Patients with Aggressive Non-Hodgkin Lymphoma Treated with CD19 CAR T Cells

Lili Zhou, Liang Aibin, MD, Shaoguang Li, Shiguang Ye, Ping Li

Blood (2019) 134 (Supplement_1): 5315.

https://doi.org/10.1182/blood-2019-130566

Published: 2019

Journal Articles

Short-Course Therapy in Newly Diagnosed Immunodeficiency-Associated Aggressive B-Cell Lymphoma

Rami Alsharif, MD, Samah Nassereddine, MD, Esma Akin, MD, Donald Karcher, MD, Mitchell Smith, MD PhD, Eduardo Sotomayor, MD, Kieron Dunleavy, MD

Blood (2019) 134 (Supplement_1): 5355.

https://doi.org/10.1182/blood-2019-124081

Published: 2019

Journal Articles

Hexokinase II Expression As a Prognosis Marker in Diffuse Large B-Cell Lymphoma (DLBCL) Pre- and Post- the Incorporation of Rituximab to Standard CHOP Chemotherapy

Juan J. Gu, MD PhD, Yizhen Liu, MD PhD, Jia Jin, Ling Yang, Zuguang Xia, Xiaojian Liu, Fangfang Lv, MD, Francisco J. Hernandez-Ilizaliturri, MD, Xiaonan Hong, Junning Cao, MD, Qunling Zhang, MD PhD

Blood (2019) 134 (Supplement_1): 5233.

https://doi.org/10.1182/blood-2019-128878

Published: 2019

Journal Articles

Optimize the Patient to Optimize the Therapy: Role of Prephase Cyclophosphamide in Aggressive Lymphoma

Nabin Karki, MBBS, Vamsi Kota, MBBS, Katherine Saunders, PharmD, Cara Iacobellis, PharmD, Anand Jillella, MD, Germame Ajebo, MD, Locke J. Bryan, MD

Blood (2019) 134 (Supplement_1): 5294.

https://doi.org/10.1182/blood-2019-129644

Published: 2019

Journal Articles

Prophylactic Use of Filgrastim on Days 7, 11 and 14 in Patients Receiving R-CHOP for Non-Hodgkin's Lymphoma

Sherief El- Shakankery, MPharm, Sumantha Gabriel, BPharm, Emma Groves, M Pharm

Blood (2019) 134 (Supplement_1): 5887.

https://doi.org/10.1182/blood-2019-124329

Published: 2019

Journal Articles

Beyond Acute Leukemia: Learner Perceptions of Inpatient Hematology Education and Deficiencies in Non-Malignant Topics

Andrew O'Brien, MD, Rakesh P. Mehta, MD

Blood (2019) 134 (Supplement_1): 5797.

https://doi.org/10.1182/blood-2019-123271

Published: 2019

Journal Articles

UM171 Modified Cord Blood Achieves Excellent Survival and Disease Control after 2 Years of Follow-up in High and Very High Risk Malignancies

Sandra Cohen, MD FRCP(C), Jean Roy, MD, Jean-Sébastien Delisle, MD PhD, Nadia M. Bambace, MD, Imran Ahmad, MD, Silvy Lachance, MD FRCP, Léa Bernard, MD, Frederic Barabe, MD, Thomas L. Kiss, MD, Lambert Busque, MD, Denis-Claude Roy, MD, Filippo Milano, MD PhD, Guy Sauvageau, MD PhD

Blood (2019) 134 (Supplement_1): 3245.

https://doi.org/10.1182/blood-2019-121698

Published: 2019

Journal Articles

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Beth A. Christian, MD, Ying Huang, MS, MA, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Jonathan E Brammer, MD, Narendranath Epperla, MDMS, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD, Farrukh T. Awan, MD, Kami J. Maddocks, MD, Kristie A. Blum, MD

Blood (2019) 134 (Supplement_1): 4082.

https://doi.org/10.1182/blood-2019-126242

Published: 2019

Journal Articles

IgM-Gammopathies Transformed into Aggressive Lymphoma: Incidence, Basal Clinical Features and Outcome of a Registry Based, Spanish Retrospective Series

Irene Dogliotti, MD, Cristina Jiménez, PhD, Federica Cavallo, MD PhD, Noemi Puig, MD PhD, Gian Maria Zaccaria, PhD, Veronica Gonzalez De La Calle, MD PhD, Maria Eugenia Sarasquete, PhD, Miguel Alcoceba, Pilar Delgado, MD, Maria Rosa López, MD, Aránzazu García Mateo, PhD, Simone Ferrero, MD, Mario Boccadoro, Marcos González, Ramón García-Sanz, MD PhD

Blood (2019) 134 (Supplement_1): 4011.

https://doi.org/10.1182/blood-2019-123353

Published: 2019

Journal Articles

Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4085.

https://doi.org/10.1182/blood-2019-129347

Published: 2019

Journal Articles

The Use of CEP (Lomustine, Etoposide and Prednisone), an All-Oral Palliative Chemotherapy Regimen, in Aggressive Lymphomas

Lakshman Vasanthamohan, MD FRCPC, Brent Parker, MD, Joy Mangel, MD FRCPC, Selay Lam, MDBSc,FRCPC, Kang Howson-Jan, MD FRCPC, Chai Wye Phua, MD FRCPC

Blood (2019) 134 (Supplement_1): 4131.

https://doi.org/10.1182/blood-2019-126997

Published: 2019

Journal Articles

Splenic Marginal Zone Lymphoma: Risk of Transformation, Clinico-Biological Features at Transformation and Prognosis

Blood (2019) 134 (Supplement_1): 4015.

https://doi.org/10.1182/blood-2019-127199

Published: 2019

NARROW

T Cell Determinants of Response and Resistance to PD-1 Blockade in Richter's Transformation

A Multicenter Study of Romiplostim to Treat Chemotherapy-Induced Thrombocytopenia in Solid Tumors and Lymphoid Malignancies

High-Throughput BCR Sequencing and Single-Cell Transcriptomics Reveal Distinct Transcriptional Profiles Associated with Subclonal Evolution of Follicular Lymphoma

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Clinical Significance of KIR Genotype in Patients with Methotrexate-Associated Lymphoproliferative Disorders

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Niveau, a Phase 3 Study for Pts with B- or T-Cell Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivo lumab in Combination with G e mcitabine, Ox a liplatin (GemOx), Plus Rit u ximab (R) in Case of B-Cell Lymphoma

Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study

Patients with Bone and Bone Marrow Involvement Had Better OS and PFS in Patients with Aggressive Non-Hodgkin Lymphoma Treated with CD19 CAR T Cells

Short-Course Therapy in Newly Diagnosed Immunodeficiency-Associated Aggressive B-Cell Lymphoma

Hexokinase II Expression As a Prognosis Marker in Diffuse Large B-Cell Lymphoma (DLBCL) Pre- and Post- the Incorporation of Rituximab to Standard CHOP Chemotherapy

Optimize the Patient to Optimize the Therapy: Role of Prephase Cyclophosphamide in Aggressive Lymphoma

Prophylactic Use of Filgrastim on Days 7, 11 and 14 in Patients Receiving R-CHOP for Non-Hodgkin's Lymphoma

Beyond Acute Leukemia: Learner Perceptions of Inpatient Hematology Education and Deficiencies in Non-Malignant Topics

UM171 Modified Cord Blood Achieves Excellent Survival and Disease Control after 2 Years of Follow-up in High and Very High Risk Malignancies

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

IgM-Gammopathies Transformed into Aggressive Lymphoma: Incidence, Basal Clinical Features and Outcome of a Registry Based, Spanish Retrospective Series

The Use of CEP (Lomustine, Etoposide and Prednisone), an All-Oral Palliative Chemotherapy Regimen, in Aggressive Lymphomas

Splenic Marginal Zone Lymphoma: Risk of Transformation, Clinico-Biological Features at Transformation and Prognosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only